Dr. Shore Discusses Therapy Combination in CRPC

Panelists: Raoul S. Concepcion, MD, Urology Associates, PC; Steve Dobbs, Urologic Associates of Oklahoma; Bryan A. Mehlhaff, MD, Oregon Urology Institute; Daniel R. Saltzstein, MD, Urology San Antonio Research;
Neal D. Shore, MD, Atlantic Urology Clinics
Published Online: Thursday, January 24, 2013
For High-Definition, Click
In this segment, Neal Shore, MD, discusses the best strategies for sequencing and and combination therapies in castration-resistant prostate cancer.

Shore says that, currently, the answers are unknown but with the multitude of investigator-initiated trials going on, the oncology community will soon be able to find combinations and sequencing methods that are not deleterious. Once a patient’s disease is confirmed, Shore believes the most impactful and well tolerated therapies should be introduced, such as sipuleucel-T.

After that, there is no pre-chemotherapy drug that is approved by the FDA, but there are high hopes for abiraterone acetate in that space. Enzalutamide is a similar drug to abiraterone in the space it’s approved in and overall efficacy. Shore believes enzalutamide in the pre-chemotherapy stage is farther off than abiraterone.

Shore admits that there will not be a single combination or sequence that will cure prostate cancer for everyone. The goal for urologists and oncologists is to cause prostate cancer to be considered a controllable, chronic disease. The only path to this endpoint is by way of data.

Peer Exchange Panel:

Raoul S. Concepcion

Raoul S. Concepcion, MD

Moderator
Editor-in-Chief,
Urologists in Cancer Care
Director of Clinical Research
Urologic Surgeon
Urology Associates, PC
Nashville, TN
 

Steve Dobbs

CEO, Urologic Associates of Oklahoma,
Tulsa, Oklahoma

Bryan A. Mehlhaff, MD

Principal Investigator, Division of Clinical Research, Oregon Urology Institute, Springfield, Oregon
 

Neal D. Shore, MD

Director, CPI, Carolina Urologic Research Center,
Grand Strand Urology/Atlantic Urology Clinics,
Myrtle Beach, South Carolina

Daniel R. Saltzstein, MD

Medical Director, Urology San Antonio Research,
San Antonio, Texas
 
View More From This Discussion
Episode 1 Prostate Cancer Management: Introduction and Overview
Episode 2 Managing ADT-Associated Skeletal-Related Events
Episode 3 Immunotherapy in Advanced Prostate Cancer, Part I
Episode 4 Immunotherapy in Advanced Prostate Cancer, Part II
Episode 5 NCCN Guidelines for Advanced Prostate Cancer
Episode 6 Treatments for Post-Docetaxel Prostate Cancer, Part I
Episode 7 Treatments for Post-Docetaxel Prostate Cancer, Part II
Episode 8 Emerging Therapies in Prostate Cancer
Episode 9 Dr. Shore Reviews Emerging Therapies in Prostate Cancer
Episode 10 Management of Patients with Advanced Prostate Cancer
Episode 11 Dr. Shore Discusses Therapy Combination in CRPC
Episode 12 Dr. Shore on the Management of Patients with CRPC
Episode 13 Reimbursement Issues in Prostate Cancer, Part I
Episode 14 Reimbursement Issues in Prostate Cancer, Part II
Episode 15 Revenue Opportunities and GPOs for Urology Groups
Episode 16 Dr. Shore on Current Clinical Trial Challenges in CRPC
Episode 17 Effective Management of Prostate Cancer Conclusion
Expert Panelists
Raoul S. Concepcion

Raoul S. Concepcion, MD

Moderator
Editor-in-Chief,
Urologists in Cancer Care
Director of Clinical Research
Urologic Surgeon
Urology Associates, PC
Nashville, TN
 

Steve Dobbs

CEO, Urologic Associates of Oklahoma,
Tulsa, Oklahoma

Bryan A. Mehlhaff, MD

Principal Investigator, Division of Clinical Research, Oregon Urology Institute, Springfield, Oregon
 

Neal D. Shore, MD

Director, CPI, Carolina Urologic Research Center, Grand Strand Urology/Atlantic Urology Clinics, Myrtle Beach,
South Carolina

Daniel R. Saltzstein, MD

Medical Director, Urology San Antonio Research, San Antonio, Texas
Online CME Activities
Free CME from PER
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment
Oncology Best Practice: Challenges in Treating Chronic Lymphocytic Leukemia – The Older Patient and Comorbid Conditions
OncoLogue: Breast Cancer Cases
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
 
More Reading
Publications
$auto_registration$